ProKidney’s stock was the biggest gainer and most actively traded on Tuesday following “very intriguing” news regarding the ...

ProKidney shares soar on promising Rilparencel mid-stage data for chronic kidney disease. But PROK stock remains a high-risk ...

ProKidney (NASDAQ: PROK) experienced a surge of 515% during Tuesday's trading session and gained additional 8.58% after-hours ...

(PROK) stock soars 56% after positive mid-stage trial results for the company's lead drug rilparencel in chronic kidney ...

Shares of ProKidney surged more than 500% on Tuesday following upbeat results from its Phase 2 REGEN-007 study and a price ...

ProKidney stock jumps after Phase 2 trial shows rilparencel significantly slowed kidney function decline in patients with ...

Key Points ProKidney announced results of a Phase 2 clinical trial.The stock, which was less than $1 per share, skyrocketed on the announcement.These 10 stocks could mint the next wave of millionaires ...

At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...

A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) ...

Shares of ProKidney rose 558% after it reported favorable results from a study of its lead drug candidate, rilparencel, in patients with chronic kidney disease and diabetes.

ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company ...